Prognosis of Human Cytomegalovirus in Cancer Patients Undergoing Chemotherapeutic Treatment in Egypt and an Emergent Prevalence of Glycoprotein B-5

The human cytomegalovirus (HCMV) is a global opportunistic β-herpes virus causing severe diseases in immune-compromised patients, such as malignant tumor especially those undergoing chemotherapeutic treatment. This study aimed to determine the prevalence of HCMV-DNA treatment naive cancer and after chemotherapy, compare between conventional nested PCR ELISA techniques for detection HCMV, detect glycoprotein B genotypes. Plasma serum samples before three chemotherapy cycles were collected from 49 chemotherapy-naive patients. DNA was extracted plasma using QIAamp® Mini kit. detected technique. Multiplex used HCMV-glycoprotein (gB) genotyping. HCMV-IgG -IgM Thirty one (63.3 %) chemotherapy-naïve patients positive HCMV-DNA; 21 which remained chemotherapy. However, 18 negative 16 became gB-5 most common genotype (80.6 %), followed by gB-1, gB-3, gB-4, gB-2. HCMV IgG exposure commonly identified Its may suggest reactivation. Egypt contrast earlier research. all indicates that endemic Egypt, necessitating development public awareness campaigns about infection preventive strategies.